Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Clinical trial NCT01101581 · WITHDRAWN

Trial details

NCT number: NCT01101581
Sponsor: Gilead Sciences
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non Hodgkin's Lymphoma NHL Aggressive NHL Diffuse Large B-cell Lymphoma

Start date: 2010-05-01
Primary completion: 2016-12-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.